Thanks Daubers. Very interesting read. While I understand that the purpose of providing this article was to demonstrate the process of a potential merger or licensing agreement, to view this in the context of IPIX is like comparing a barrel of fresh, juicy oranges that are highly desired to a crate of old, beginning to rot apples that the seller may be pushing but upon close inspection, nobody wants to buy. Just right off the bat, I am assuming, perhaps incorrectly but I doubt it, that the company with the desired drug had a competent CEO and management team and a legitimate Board. I do not see that with IPIX. Also, the stock price initially was around $81 dollars and the merger brought a $218 value to the pps, almost 3 times over the pps. Three times over IPIX's pps would be 24 cents.